Sezary Syndrome Latest Advances

Relapsed/refractory mycosis fungoides and Sezary syndrome: biology, clinical manifestations and therapeutic options.

Journal: Leukemia & lymphoma

Published: December 25, 2025

Clinical Implications of the Skin Microbiota in the Therapy of Cutaneous T Cell Lymphoma: A Scoping Review.

Journal: Dermatology and therapy

Published: September 19, 2025

Clinical and Prognostic Features of Erythrodermic Cutaneous T-Cell Lymphoma: A Retrospective Study of 35 Patients.

Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology

Published: August 27, 2025

Retrospective Analysis of Second Primary Malignancies in Patients with Mycosis Fungoides and Sézary Syndrome in Croatia.

Journal: Dermatology practical & conceptual

Published: August 24, 2025

Immune pathways, current and potential therapies in Mycosis fungoides and Sezary syndrome.

Journal: Expert review of clinical immunology

Published: July 14, 2025

Immune pathways, current and potential therapies in Mycosis Fungoides and sezary syndrome.

Journal: Expert review of clinical immunology

Published: July 14, 2025

New nonchemotherapy treatment options for cutaneous T-cell lymphomas an update.

Journal: Expert review of anticancer therapy

Published: July 09, 2025

Incidence and Mortality of Mycosis Fungoides and Sezary Syndrome: A Nationwide Registry Study in Finland.

Journal: Acta dermato-venereologica

Published: June 30, 2025

Dual TRBC1-CD3 Immunohistochemistry Shows High Diagnostic Utility in Differentiating Mycosis Fungoides/Sezary Syndrome From Reactive Inflammatory Dermatoses in Skin Biopsies.

Journal: The American journal of surgical pathology

Published: June 24, 2025

[18F]FDG PET/CT revealing extensive cutaneous involvement in Sézary syndrome.

Journal: Nuclear medicine review. Central & Eastern Europe

Published: June 20, 2025

Unraveling the role of chemokines in cutaneous T-cell lymphoma: expression levels at different stages.

Journal: Frontiers in immunology

Published: June 13, 2025

An evaluation of denileukin diftitox for the treatment of relapsed or refractory cutaneous T-cell lymphoma.

Journal: Expert opinion on biological therapy

Published: June 09, 2025